$599

Enicepatide “At Least as Good as Tirzepatide;” Roche ADA 2026 Investor Event

Roche hosted an investor event in conjunction with ADA 2026 and provided updates across its obesity pipeline, including future development plans for enicepatide and petrelintide (view slides). Notably, the company has also discontinued development of CT-868 for the obese + T1DM population, despite presenting positive Ph2 data during ADA. Below, FENIX provides highlights and insights from the investor webcast.

This content is for Read Less members only.
Already a member? Log in here